Posted: January 22, 2008

Molecular Profiles Introduces New Nanoscale Predictive Analytical Screening Solution for APIs

(Nanowerk News) Molecular Profiles, a global leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors, announces the latest addition to its comprehensive nanoscale analytical services offering, nanoPASSTM (nanoscale Predictive Analytical Screening Solution). This innovative new service platform is a comprehensive suite of complementary analytical techniques designed to optimise solid state selection of APIs and provide further insight into the formulation of APIs and excipients.
Processing of drug substance and excipients can have a significant effect on surface properties and subsequent stability/bioavailability of the active. To decide on the best formulation option, full understanding of bulk and surface physicochemical properties is required. Enabling technologies allow empirical observations such as batch-to-batch variation, cohesive tendency and powder flow to be correlated to actual physicochemical properties.
The nanoPASSTM suite has been equipped with an extended range of analytical techniques, including nanoscale determination of materials, mechanical and cohesive properties, chemical spectroscopy, physical properties (XRPD and thermal techniques), high-resolution spatial mapping and imaging of chemical, physical, thermal and material properties. The unique solid state characterisation capabilities of the service platform enable users to compare bulk and surface properties of drug substance, excipients, granules and aggregates providing them with a detailed physicochemical profile.
The nanoPASSTM service platform requires only small amounts of sample to provide precise and dependable material characterisation. An example of the power of the analytical benefits afforded by nanoPASSTM is the pre-formulation screening of the physical properties of single formulated particles using Atomic Force Microscopy (AFM), which provides deep insight into the pharmaceutical function of developmental products.
“The introduction of this novel service platform further demonstrates our dedication to providing a high quality and reliable extension to the R&D capabilities within pharmaceutical companies,” comments Dr. Nikin Patel, CEO, Molecular Profiles. “Our team of specialised, experienced scientists will be building upon this platform to develop an extended range of service offerings intended to provide our customers with even more clarity and choice.”
More information about nanoPASSTM and Molecular Profiles’ award-winning contract research services is available at, by e-mail at [email protected], alternatively, call Dr. Nikin Patel on +44 115 8718888.
About Molecular Profiles
Molecular Profiles is a leader in the provision of innovative contract research services to the pharmaceutical, biopharmaceutical and biomedical sectors worldwide. The company is a recipient of a Queen’s Award for Enterprise in the Continuous Innovation and Development category. The award saw the company and its complete range of services recognised as one of the UK’s most innovative during 2007. The services include nanoscreening technology for predicting the ease of development of a new medicine, a deformulation service for identifying problems with a product down to the nanoscale, and advanced imaging for viewing and optimising the internal structure of products.
Source: Molecular Profiles
Subscribe to a free copy of one of our daily
Nanowerk Newsletter Email Digests
with a compilation of all of the day's news.
These articles might interest you as well: